

Sender	Meeting Date	Comment
Maryellen Cronin	9/8/2023	<p>Please do not approve the dispensary at 5 Washington Street Mount Holly. Only 5ft separate my apartment building from the proposed dispensary. There is no parking of any kind and this location is not good for a dispensary. I am not against cannabis, I am just against this location. A cannabis retail place was already approved in our town and it is walking distance from this one. This will seriously impact the quality of our lives. There are more than 8 apartments right next to this location. Please deny 5 Washington Street Mount Holly a license or come to the site and see for yourself that it is not a good location. Fire and Oak LLC is the applicant. Thank you!</p>
Luke Seigel	9/8/2023	<p>Please give medical patients back our right to cultivate our medicine in our homes and gardens. It is shameful what's going on in this state. It's a blatant money grab. Pay to play. And we're paying attention. One hand washes the other in NJ. I don't know why we ever expected this to be different. Even the "gifting" shops seem to operate with the help of police. If you have money you can "gift" cannabis for profit but NJ patients still cannot access organic medicine or medicine that treats our symptoms. Most "budtenders" are uninformed and have no clue what fertilizers are inside the medicine they are pushing. Imagine if your pharmacist wasn't sure what was in your medicine! Help us by giving us back our right to grow (& know) what we are consuming is healthy and going to help us. Why is NJ so far behind the rest of tri state? How come medical patients are continuously overlooked and treated secondary to rec consumers? Where is the compassion? I implore you to help NJ medical patients. We aren't the ones looking to get rich by growing the fastest plants with the cheapest fertilizers for our profit margins. Many of us have had our lives saved by cannabis and require our medicine to stay the course.</p>
Chereese Tulino	9/8/2023	<p>Priority applications, I have contacted NJCRC, NJ technical help line and my senator to assist me since August 8. My application is complete, however, there is a technical issue when I attempt to submit. I have not received any response from the multiple offices I have reached out to.</p>

<p>Natalie Diaz, Esq.</p>	<p>9/8/2023</p>	<p>There are apparent inconsistencies in the Commission's enforcement of the 15-day deadline before a conditional expiration to submit an extension request. This raises transparency and fairness questions in the regulatory process and questions regarding who holds discretion to enforce. Consistent deadline application by regulatory bodies is crucial for public trust and industry fairness. I urge the Commission to promptly review and address these issues, including revising the notice of conditional expiration to prevent confusion, as it only pertains to annual renewals.</p>
<p>Gaetano Lardieri</p>	<p>9/8/2023</p>	<p>Cannabis Regulatory Commission Clinical Registrant License Comments submitted by Gaetano Lardieri 20Aug2023 Good morning CRC Chair, Commissioners and distinguished guests. Gaetano Lardieri from Newark NJ. Cannabis/Psychedelics advocate and Researcher. My overall general comments provided for your consideration today are formulated after a complete and careful review of the recent document/proposed amendment/New Rules (Clinical Registrant License (N.J.A.C. 17:30A-1.2 and 7.1, N.J.A.C 17:30A-7.12 and 7A) submitted for public comment by the CRC on 07Aug2023 filed 11Jul2023. I am here to strongly advocate for the establishment of a groundbreaking department within the existing framework of the Cannabis Regulatory Commission (CRC). A department that is poised to be the vanguard in the realm of cannabis clinical research and development. We propose the creation of the Department of Cannabis Clinical Research, Development and Management (CCRDM). A department that will serve as a pivotal hub and nexus for cannabis research in the state of New Jersey. Why, you might ask, do we need a department dedicated solely to cannabis clinical research within the CRC? The answer lies in the complexity and expertise required to navigate the uncharted waters of clinical research, especially when it involves substances classified by the Federal Government as Schedule I</p>

		<p>drugs - (perhaps one day Schedule III according to the latest news from HHS).</p> <p>Stay tuned for how that very interesting recent development rolls out.</p> <p>First and foremost, the Department of Cannabis Clinical Research, Development and Management (CCRDM) would require a Chair level position appointed by Governor Murphy.</p> <p>The Chair would report directly to the Governor of New Jersey and also report to the public on a scheduled basis through the CRC on the departments progress and research status.</p> <p>This Chair would act and be held to the same standards and level as a medical director in an organization conducting clinical trial research with human subjects.</p> <p>This department would have dedicated specialized research staff and its own budget.</p> <p>The Chair of this newly created department should hold either an MD or a PhD degree. Furthermore, the Chair would be required to have extensive expertise in the design, implementation, and management of clinical trials involving Schedule I drugs and clinical research study participants.</p> <p>One doesn't have to look far to fulfill this Chair position as the talent pool exists right here in the state of New Jersey or no further than our neighbor to the West (PA) or the East (NY).</p> <p>Some of the Chairs initial responsibilities would be to establish, staff, and eventually manage the entire department.</p> <p>This individual will be the linchpin, steering the ship of innovation and progress in cannabis clinical research.</p> <p>One might wonder, why should we create a separate department and appoint a Chair at the level of a medical director within the CRC?</p> <p>The answer is clear: the complexities associated with cannabis clinical research demand specialized attention.</p> <p>Cannabis, despite its growing acceptance, remains a Schedule I substance at the federal level, a classification that comes with a myriad of regulatory and scientific challenges.</p> <p>To conduct meaningful research that unlocks the therapeutic potential of cannabis, we need a department that can navigate these regulatory and scientific complexities efficiently and effectively with</p>
--	--	---

		<p>overall patient safety and research integrity at the forefront.</p> <p>This department must stand independently within the CRC, reporting directly to the Governor of New Jersey, ensuring that research initiatives are free from unnecessary bureaucratic hurdles and comply with the highest standards of research that involve human subjects.</p> <p>Furthermore, this new department should have its own budget, funded through cannabis taxes and, potentially, opioid settlement funds.</p> <p>Such financial independence is crucial to foster innovation and scientific rigor in can</p>
--	--	---

Gaetano Lardieri	9/8/2023	<p>Such financial independence is crucial to foster innovation and scientific rigor in cannabis clinical research. It will allow the Chair and the department to attract top talent, acquire cutting-edge technology, and ensure necessary resources to pursue pioneering research endeavors.</p> <p>One of the pivotal responsibilities of the Chair would be to establish a Central Institutional Review Board (IRB) within this newly formed department. This Central IRB would serve as a hub for approving, coordinating, funding, and monitoring clinical research initiatives related to cannabis within the purview of the CRC or conducted outside the CRC at institutions that hold a CRC state issued cannabis research license.</p> <p>This Central IRB would be a beacon of transparency, rigor, and accountability for all cannabis clinical research approved and under the supervision of the newly created department. It would streamline the approval process, ensuring that research is conducted ethically, efficiently, and in compliance with all regulations. It shall have the responsibility of reviewing, approving and overseeing of the Clinical Registrant Licenses, contracts and partnerships. The department should serve as a liaison between the clinical registrant license holders, the public and the state.</p> <p>The department would ensure and oversee the integrity of all research collaborations and contracts. In conclusion, I implore you to consider the establishment of this new department, the Department of Cannabis Clinical Research, Development and Management (CCRDM) within the CRC as a visionary step toward harnessing the full potential of cannabis for the betterment of patients, the state of New Jersey and society in general. This department, led by a Chair of the highest caliber, will not only navigate the complexities of cannabis research but will also position New Jersey at the forefront of medical innovation and scientific discovery for cannabis research.</p> <p>Let us seize this opportunity to invest in the future, push the boundaries of knowledge, and improve the lives of patients, and our citizens through a pioneering vision for cannabis research in the state of new Jersey.</p> <p>In follow up I will be submitting further detailed</p>
------------------	----------	---

		<p>comments on specifics of the Medical Cannabis Rules document recently issued by the CRC. Thank you for your time and consideration.</p>
--	--	--

<p>Michael Edelstein</p>	<p>9/8/2023</p>	<p>The New Jersey State Policy Lab, based out of Rutgers University's Eagleton Institute, conducted a poll of New Jerseyans in the Summer of 2022 that they released in March of this year. They asked respondents about their opinions regarding cannabis legalization and among other questions asked respondents if they agree that "It should be legal for an adult to grow cannabis for personal use". The results from this poll are overwhelming and deeply concurrent with real world data.</p> <p>No matter how respondents were separated into cohorts, whether by political affiliation, if children are at home, if they currently use cannabis, if they are homeowners or renters, education level, income level, race, gender, age...EVERY SINGLE COHORT supports the legalization of home-grow either strongly or somewhat. That includes Republicans (54.2% support), those over the age of 65 (50% support while 44.5% oppose, others unsure/no response), Asians (56.2% support), and those with a High School diploma or less education (56.5% support). While these groups represent the lowest levels of support among all groups, even they ALL support with a majority of at least 50% that "It should be legal for an adult to grow cannabis for personal use".</p> <p>Overall, 63% of respondents agree with home-grow legalization. 67% agree with cannabis legalization. There is a very clear message coming from the residents of the State of New Jersey. New Jerseyans overwhelmingly support the legalization of home-grown cannabis.</p> <p>Michigan legalized homegrow before retail recreational cannabis became legal. In the 3 short years since legalization, Michigan has gone from raising \$45.7M in tax revenue in 2020 to \$325M in 2022. Regardless of Michigan's higher tax rate and ~12% larger population, the state's tax revenue grew by over 700% in 2 years! All the while, homegrow of up to 12 plants was legal in the State of Michigan. In fact, it was legal for a full year before retail cannabis became available.</p> <p>Home-grow does not prevent the success of the cannabis retail market and it does not significantly</p>
--------------------------	-----------------	---

		<p>hamper state tax revenues from cannabis sales.</p> <p>Having legal cannabis without homegrow is untenable and, frankly, absurd. It does not stand to reason and it flies in the face of the social equity that legalization sought to ensure. Growing even 1 oz of cannabis flower is considered a 3rd degree crime in New Jersey, punishable by up to 5 years in jail and a \$25,000 fine. The realities are more akin to drug court, small fines, seizure of private property, potential loss of employment, custody of children...the list goes on. All for growing a plant that I can buy at the store down the street. Is this fair? Is this socially equitable? Is this the will of the people of New Jersey?</p> <p>What are we doing? All of this to hypothetically protect the interests of Multi-State Operating cannabis corporations that sell pesticide treated cannabis at black market prices. We know how to help the cannabis market. More licenses, more cultivators, more retailers, lower prices.</p> <p>The possible reclassification of cannabis to a Schedule III drug will eliminate the tax burden of Section 280e on cannabis-related businesses will be an enormous boon to the industry as a whole.</p> <p>New York included a provision in their cannabis legalization act that home-grow will become legal within 18 months of the first retail sale. That sale occurred in New York in December 2022, meaning July 2024 will be the 18 month mark.</p> <p>September 2023 marks the 18th month since the first retail sale of cannabis in NJ, which occurred in April 2022.</p> <p>It is time to respect the will of the people of New Jersey. It is time to align ourselves with the 19 other States that allow for recreational homegrow. It is time to allow medical patients who have been told since 2010 that medical homegrow will be reconsidered in the future.</p> <p>There is no sense in which we can continue to illegalize recreational and medical homegrow in the State of New Jersey.</p>
--	--	---